글로벌 마이세토마 치료 시장 - 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 마이세토마 치료 시장

글로벌 마이세토마 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 위에 언급된 연구 예측 기간 동안 4.90%의 건강한 CAGR로 성장하고 있다고 분석합니다.

마이세토마는 토양과 물에 서식하는 특정 유형의 박테리아와 균류에 의해 발생하는 질병입니다. 박테리아는 발 피부 의 균열을 통해 신체로 유입될 수 있습니다 . 이로 인해 감염이 증가하고 통증은 줄어들 수 있지만 피부 아래에 노폐물 덩어리가 형성되어 결국 밑에 있는 뼈에 영향을 미칠 수 있습니다. 마이세토마는 박테리아(방선균종) 또는 균류(진균종)의 전파로 인해 발생합니다. 실제 사례 수는 훨씬 더 많을 가능성이 있습니다. 1950년과 2017년 사이의 과학 기사에 대한 2017년 검토에 따르면 약 17,607건이 보고되었습니다.

마이세토마는 모든 연령대의 사람들에게 감염되며 남성에게 꽤 흔합니다. 이 질병은 주로 적도 근처에 위치하고 건조한 기후를 가진 아프리카, 라틴 아메리카 및 아시아의 농촌 지역에 사는 사람들에게 영향을 미칩니다. 마이세토마에 걸린 사람들은 종종 의료 및 약물에 대한 접근성이 제한적인 외딴 지역에 살고 있습니다. 마이세토마는 사람들이 일을 멈추고 낙인을 찍을 수 있는 심각한 신체적 기형으로 이어질 수 있습니다. 최근 몇 년 동안 마이세토마 사례의 최대 수는 미국에서 보고되었습니다. 1890년부터 2020년까지 미국에서 보고된 사례 수는 감소했습니다. 마이세토마 치료는 치유하는 데 시간이 오래 걸리지만 비용이 증가하여 감당할 수 없는 요법으로 구성됩니다. 치료 유형은 박테리아 (방선균종) 또는 진균(진균종)으로 인해 발생하는지에 따라 달라집니다. 방선균종은 항생제 로 치료할 수 있습니다 . 진균종은 장기 항진균제 로 치료되지만 완전히 효과적이지 않을 수 있습니다.

The increased prevalence of mycetoma, rise in geriatric population, increased count in research and development for novel therapies, number of government initiatives, investment by R&D in pharmaceutical companies, increased demand of antibiotics for Mycetoma Treatment  are predicted to drive the market growth. However, the lack of health remuneration policies, rise in cost, lack of proper sanitation, side effects associated with the use of antibiotics is expected to hinder the market growth. The rise of emerging markets in developing countries, rise of untapped opportunities, upcoming healthcare clinics, use of laser treatment to remove boils are the opportunities which are projected to bolster the market growth. The lack of expertise, rise in product (antibiotic) recalls, and use of alternatives other than antibiotics are the challenges which can tamper the market growth.

This mycetoma treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Mycetoma Treatment Market Scope and Market Size

The mycetoma treatment market is segmented on the basis of type, antibiotic type, treatment type, route of administration, mode of purchase and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the mycetoma treatment market is segmented into actinomycetoma, eumycetoma.
• On the basis of antibiotic type, the mycetoma treatment market is segmented into Netilmicin-TS, Sulfonamides DDS (4,4 diaminodiphenyl-sulfone).
• On the basis of treatment type, the mycetoma treatment market is segmented into medication, supportive care .
• On the basis of route of administration, the mycetoma treatment market is segmented into oral, parenteral.
• On the basis of mode of purchase, the mycetoma treatment market is segmented into prescription and over the counter.
• On the basis of distribution channel, the mycetoma treatment market has also been segmented into hospital pharmacies, retail pharmacies, online pharmacies and others.

Mycetoma Treatment Market Country Level Analysis

Mycetoma treatment market is analysed and market size information is provided by country, type, antibiotic type, treatment type, route of administration, mode of purchase and distribution channel as referenced above.

The countries covered in the mycetoma treatment  market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America is expected to hold the largest market share due to the rising number of mycetoma cases, increased awareness among the population base about the prevention of mycetoma, affordability of antibiotics. Asia-Pacific is also expected to account for the second largest market share due to the rise in point of care diagnostics, technological advancements for treatment of mycetoma, untapped opportunities in emerging markets.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Mycetoma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Mycetoma Treatment Market Share Analysis

Mycetoma Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to mycetoma treatment market.

마이세토마 치료 시장에서 다루는 주요 업체는 Biochem Pharma, Zydus Cadila, GSK, Vernalis (R&D) Limited, IrisFarma, Sun Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Galderma Laboratories, Mayne Pharma Group, Akorn, Mylan NV, Johnson & Johnson Services, Inc, Medimetriks Pharmaceuticals, Inc, F-Hoffmann-La Roche 등 국내 및 글로벌 업체입니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.

SKU-60425